We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A pending trade agreement with Australia could block the importation of prescription drugs from Australia into the U.S. and set a precedent for blocking drug importation from other countries as part of future free trade agreements (FTAs), a member of Congress has warned.
A key Republican lawmaker is urging the General Accounting Office (GAO) to conduct a broad review of the FDA’s drug safety arm, saying he is concerned that a department charged with protecting the public interest appears to be a “lapdog” with little independence.
Hours after being chastised by Rep. Henry Waxman (D-Calif.) for dropping out of a major clinical trial involving HIV treatment in African and other developing countries, GlaxoSmithKline (GSK) reversed course and said it would participate in the study.
Public hospitals and community health clinics participating in a federal drug discount program were overcharged $41.1 million in a single month by pharmaceutical companies, according to a report released by the HHS Office of Inspector General (OIG).
Final action on a rule governing labeling for human prescription drugs is set for October, according to the FDA’s Semiannual Regulatory Agenda, published in the Federal Register earlier this week.
Oral anticancer therapies, as well as treatments for multiple sclerosis and arthritis, will be covered under the Medicare Part B replacement drug demonstration project now under way, according to HHS Secretary Tommy Thompson.
Two House committee chairmen last week asked that HHS, the FDA, the FTC and 12 other agencies to reveal the extent of awards, contracts and other agreements between their employees and outside interests.
Under a sweeping ethics reform plan unveiled by the National Institutes of Health (NIH) director at a House Oversight and Investigations Subcommittee hearing last week, NIH employees will be restricted from performing outside consulting work for industry.
National Institutes of Health (NIH) employees will be restricted from performing outside consulting work for industry under a sweeping ethics reform plan unveiled by the NIH director at a House Oversight and Investigations Subcommittee hearing yesterday.
Two House committee chairmen Friday asked that 15 federal agencies -- including the HHS, the FDA and the FTC -- reveal the extent of awards, contracts and other agreements between their employees and outside interests.